Professor Josephine Bunch is currently leading the Cancer Research UK Grand Challenge programme. Josephine is Co-Director of the National Centre of Excellence in Mass Spectrometry Imaging (NiCE-MSI) at NPL and Chair of Biomolecular Mass Spectrometry at Imperial College London. At NPL, Josephine leads research and metrology in MALDI and ambient mass spectrometry imaging within NiCE-MSI. Josephine previously led a research group in mass spectrometry imaging at the University of Birmingham, where she was a Lecturer in Chemistry and Imaging in the School of Chemistry and PSIBS Doctoral Training Centre (2009–2013).
Prof Ian Gilmore is Head of Science at NPL and founder of the National Centre of Excellence in Mass Spectrometry Imaging (NiCE-MSI) at NPL, where he innovated the revolutionary 3D OrbiSIMS instrument. Ian is a Fellow of the Institute of Physics (IOP) and the American Vacuum Society, has been awarded the IOP Clifford Paterson Medal and the Rivière Prize, and leads international standardisation in surface chemical analysis. In the Grand Challenge, the Gilmore group will lead the high-resolution 2D and 3D SIMS imaging.
Prof John Marshall joined the Imperial Cancer Research Fund laboratories in London in 1984. After studying photodynamic therapy, he began his PhD studies on the role of integrins in melanoma, before turning to the study of carcinoma integrins. In 2004, he moved to Barts Cancer Institute in London, since then he has published over 30 papers on v6 showing that it represents a major target for imaging and therapy of multiple types of carcinoma. He developed an imaging agent for v6 developed from foot-and-mouth-disease virus which is being used for human PET imaging studies and has co-developed a human v6-blocking antibody with AstraZeneca-Medimmune due to enter a CRUK-funded Phase I trial in pancreatic and breast cancers in early 2018. In the Grand Challenge, the Marshall group will deliver the imaging CyTOF analysis.
Prof Owen Sansom is interim director of the Cancer Research UK Beatson Institute. He has published over 200 papers in a research career spanning 16 years. Owen gained his PhD in 2001 working on in vivo models of apoptosis in cancer. Since then, Owen has been instrumental in determining the molecular hallmarks and cell of origin of epithelial cancers (colorectal and pancreatic). Using this experience, the Sansom laboratory will provide the Grand Challenge team with the in vivo models that will be mapped in 3D.
Dr Richard Goodwin is a Principal Scientist at AstraZeneca working in the department of Drug Safety and Metabolism. Richard leads the mass spectrometry imaging (MSI) group that studies the distribution of drugs in tissues to understand their efficacy and safety. He also studies MSI data to understand disease biology at the molecular level to help devise new drugs. Richard's role within the Grand Challenge team is to help perform inter-site experiments, then translate the findings into an industry setting and disseminate, so the results can have the most impact on the development of new oncology medicines.
Dr Mariia Yuneva's cancer metabolism research began at Cold Spring Harbour Laboratories in New York, where she studied the relationship between oncogenic transformation and nutrient requirements. Mariia then moved to the University of California, San Francisco, to evaluate the relationship between oncogenic transformation and metabolic changes in vivo in mouse models of tumorigenesis. Since 2013, Mariia has led a group at the Francis Crick Institute. In the Grand Challenge, Mariia's group will provide in vivo and ex vivo models of mouse and human primary breast cancers and their metastases.
Following a PhD at the University of Cambridge and postdoctoral training at Harvard Medical School, Dr George Poulogiannis joined the Institute of Cancer Research (ICR) in 2014 to lead the Signaling and Cancer Metabolism team, with the focus to understand the signaling and metabolic networks that are related to cell growth and malignant transformation. George's contribution to the Grand Challenge will be to lead the work in understanding the therapy sensitivity pattern of metabolically-distinct tumour phenotypes using genetic and pharmacological approaches across in vitro and in vivo models.
Prof Zoltan Takats has been doing mass spectrometry-related research for more than 15 years, and is the inventor of multiple analytical methods allowing direct analysis of biomolecular systems. He currently works as Professor of Analytical Chemistry at Imperial College London. Present research interests include the application of ambient ionization methods in surgical metabonomics and development of mass spectrometric imaging techniques for the rapid phenotyping of cancer patients. In the Grand Challenge, the Takats group will help deliver multi-modal MS imaging and lead REIMS and iKNIFE studies.
Prof Kevin Brindle is Professor of Biomedical Magnetic Resonance at the University of Cambridge and a senior group leader in the CRUK Cambridge Institute. Kevin was elected a Fellow of the Academy of Medical Sciences in 2012 and to the European Academy of Cancer Sciences in 2014. He was awarded the European Society of Molecular Imaging Award in 2013 and the Gold Medal of the World Molecular Imaging Society in 2014. In the Grand Challenge, the Brindle group will be responsible for recruiting patients for hyperpolarized 13C imaging in the clinic, and for subsequent collection of tumour material at surgery for mass spectrometry imaging ex vivo and for isolation of patient-derived tumour cell lines and production of patient-derived orthotopic tumour xenografts.
Simon Barry is a Senior Principal Scientist in the IMED Oncology at AstraZeneca, Cambridge UK. He has been involved in discovering and developing both small and large molecule therapeutics as well as nanoparticle therapeutics targeting both tumour cell and stromatolites pathways. His research focuses on the cross talk between the tumour and its micro environment, as well as elucidating drug mode of action and mechanisms underpinning therapeutic benefit. AstraZeneca's Oncology group will support the Grand Challenge experimentally with specialist technical and scientific contributions, as well as with its portfolio of therapeutics, and help translate the findings to advance patient treatment options.
Harry C. Hall
Harry's a successful Marketing professional with a background in Advertising and Design. Bowel Cancer in 2002 motivated involvement with the treatment unit's User Group. A founder member of W London Cancer Network Partnership Group and ultimately chair, he also sat on the Network’s Executive Board. He joined senior management at NHS Training for Innovation in 2007, involved in Patient Safety projects including the National Early Warning Score NEWS. Harry represented cancer patients on the London Cancer Alliance LCA, Clinical Board and Colorectal Cancer Pathway Group. He sits on the NIHR Imperial BRC PPI Panel, Imperial College & Partners PPI Research Forum and the CRUK Imperial Centre PPI Group.